Carfilzomib for relapsed or refractory multiple myeloma.
Journal: 2018/November - The Lancet Oncology
ISSN: 1474-5488
Relations:
Diseases
(1)
Conditions
(1)
Chemicals
(2)
Organisms
(1)
Similar articles
Articles by the same authors
Discussion board
Collaboration tool especially designed for Life Science professionals.Drag-and-drop any entity to your messages.